Evropska unija - slovenščina - EMA (European Medicines Agency)

mylan s.a.s - ambrisentan - hipertenzija, pljučnica - antihipertenzivi, - ambrisentan mylan je primerna za zdravljenje pljučne arterijske hipertenzije (pah) pri odraslih bolnikih, ki funkcijski razred (fc), ii in iii, vključno z uporabo v kombinaciji zdravljenja. učinkovitost so pokazali pri idiopatskem pah (ipah) in pri pah, povezani z boleznijo vezivnega tkiva. ambrisentan mylan je primerna za zdravljenje pljučne arterijske hipertenzije (pah) pri odraslih bolnikih, ki funkcijski razred (fc), ii in iii, vključno z uporabo v kombinaciji zdravljenja. učinkovitost so pokazali pri idiopatskem pah (ipah) in pri pah, povezani z boleznijo vezivnega tkiva.

Evropska unija - slovenščina - EMA (European Medicines Agency)

mylan ireland limited - abirateron acetat - prostatične neoplazme - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Evropska unija - slovenščina - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , trojna kombinacija terapija), kot dodatek k prehrani in vadbi pri bolnikih neustrezno nadzorovano na maksimalno dopustne odmerek metforminom in sulfonil sečnine. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Evropska unija - slovenščina - EMA (European Medicines Agency)

mylan ireland limited - dimetil fumarat - multiplo sklerozo, recidivno-nakazila - imunosupresivi - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Evropska unija - slovenščina - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomide - multiplo sklerozo, recidivno-nakazila - imunosupresivi - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Evropska unija - slovenščina - EMA (European Medicines Agency)

mylan pharmaceuticals limited - olanzapin - schizophrenia; bipolar disorder - psiholeptiki - adultsolanzapine je primerna za zdravljenje shizofrenije. olanzapin je učinkovita pri ohranjanju klinično izboljšanje, med nadaljevanje terapije pri bolnikih, ki so pokazali začetni odziv zdravljenje. olanzapin je primerna za zdravljenje zmerno do hudo manične epizode. pri bolnikih, katerih manične epizode se je odzvala na olanzapin zdravljenje, olanzapin, je indicirano za preprečevanje ponovitve pri bolnikih z bipolarno motnjo.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

mylan ireland limited - okskarbazepin - filmsko obložena tableta - okskarbazepin 300 mg / 1 tableta - okskarbazepin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

mylan ireland limited - okskarbazepin - filmsko obložena tableta - okskarbazepin 600 mg / 1 tableta - okskarbazepin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

mylan ireland limited - okskarbazepin - filmsko obložena tableta - okskarbazepin 150 mg / 1 tableta - okskarbazepin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

mylan ireland limited - okskarbazepin - filmsko obložena tableta - okskarbazepin 150 mg / 1 tableta - okskarbazepin